White Matter Changes in Cervical Dystonia Relate to Clinical Effectiveness of Botulinum Toxin Treatment
In a previous report showing white matter microstructural hemispheric asymmetries medial to the pallidum in focal dystonias, we showed preliminary evidence that this abnormality was reduced 4 weeks after botulinum toxin (BTX) injections. In the current study we report the completed treatment study i...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-04-01
|
Series: | Frontiers in Neurology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fneur.2019.00265/full |
id |
doaj-e01c2f4025cc42c6b60f44cfb70e9866 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Anne J. Blood Anne J. Blood Anne J. Blood Anne J. Blood Anne J. Blood Anne J. Blood John K. Kuster John K. Kuster John K. Kuster John K. Kuster John K. Kuster Jeff L. Waugh Jeff L. Waugh Jeff L. Waugh Jeff L. Waugh Jeff L. Waugh Jacob M. Levenstein Jacob M. Levenstein Jacob M. Levenstein Trisha J. Multhaupt-Buell Lewis R. Sudarsky Lewis R. Sudarsky Hans C. Breiter Hans C. Breiter Hans C. Breiter Hans C. Breiter Hans C. Breiter Hans C. Breiter Hans C. Breiter Nutan Sharma Nutan Sharma Nutan Sharma |
spellingShingle |
Anne J. Blood Anne J. Blood Anne J. Blood Anne J. Blood Anne J. Blood Anne J. Blood John K. Kuster John K. Kuster John K. Kuster John K. Kuster John K. Kuster Jeff L. Waugh Jeff L. Waugh Jeff L. Waugh Jeff L. Waugh Jeff L. Waugh Jacob M. Levenstein Jacob M. Levenstein Jacob M. Levenstein Trisha J. Multhaupt-Buell Lewis R. Sudarsky Lewis R. Sudarsky Hans C. Breiter Hans C. Breiter Hans C. Breiter Hans C. Breiter Hans C. Breiter Hans C. Breiter Hans C. Breiter Nutan Sharma Nutan Sharma Nutan Sharma White Matter Changes in Cervical Dystonia Relate to Clinical Effectiveness of Botulinum Toxin Treatment Frontiers in Neurology botulinum toxin basal ganglia dystonia ansa lenticularis white matter plasticity diffusion tensor imaging |
author_facet |
Anne J. Blood Anne J. Blood Anne J. Blood Anne J. Blood Anne J. Blood Anne J. Blood John K. Kuster John K. Kuster John K. Kuster John K. Kuster John K. Kuster Jeff L. Waugh Jeff L. Waugh Jeff L. Waugh Jeff L. Waugh Jeff L. Waugh Jacob M. Levenstein Jacob M. Levenstein Jacob M. Levenstein Trisha J. Multhaupt-Buell Lewis R. Sudarsky Lewis R. Sudarsky Hans C. Breiter Hans C. Breiter Hans C. Breiter Hans C. Breiter Hans C. Breiter Hans C. Breiter Hans C. Breiter Nutan Sharma Nutan Sharma Nutan Sharma |
author_sort |
Anne J. Blood |
title |
White Matter Changes in Cervical Dystonia Relate to Clinical Effectiveness of Botulinum Toxin Treatment |
title_short |
White Matter Changes in Cervical Dystonia Relate to Clinical Effectiveness of Botulinum Toxin Treatment |
title_full |
White Matter Changes in Cervical Dystonia Relate to Clinical Effectiveness of Botulinum Toxin Treatment |
title_fullStr |
White Matter Changes in Cervical Dystonia Relate to Clinical Effectiveness of Botulinum Toxin Treatment |
title_full_unstemmed |
White Matter Changes in Cervical Dystonia Relate to Clinical Effectiveness of Botulinum Toxin Treatment |
title_sort |
white matter changes in cervical dystonia relate to clinical effectiveness of botulinum toxin treatment |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Neurology |
issn |
1664-2295 |
publishDate |
2019-04-01 |
description |
In a previous report showing white matter microstructural hemispheric asymmetries medial to the pallidum in focal dystonias, we showed preliminary evidence that this abnormality was reduced 4 weeks after botulinum toxin (BTX) injections. In the current study we report the completed treatment study in a full-size cohort of CD patients (n = 14). In addition to showing a shift toward normalization of the hemispheric asymmetry, we evaluated clinical relevance of these findings by relating white matter changes to degree of symptom improvement. We also evaluated whether the magnitude of the white matter asymmetry before treatment was related to severity, laterality, duration of dystonia, and/or number of previous BTX injections. Our results confirm the findings of our preliminary report: we observed significant fractional anisotropy (FA) changes medial to the pallidum 4 weeks after BTX in CD participants that were not observed in controls scanned at the same interval. There was a significant relationship between magnitude of hemispheric asymmetry and dystonia symptom improvement, as measured by percent reduction in dystonia scale scores. There was also a trend toward a relationship between magnitude of pre-injection white matter asymmetry and symptom severity, but not symptom laterality, disorder duration, or number of previous BTX injections. Post-hoc analyses suggested the FA changes at least partially reflected changes in pathophysiology, but a dissociation between patient perception of benefit from injections and FA changes suggested the changes did not reflect changes to the primary “driver” of the dystonia. In contrast, there were no changes or group differences in DTI diffusivity measures, suggesting the hemispheric asymmetry in CD does not reflect irreversible white matter tissue loss. These findings support the hypothesis that central nervous system white matter changes are involved in the mechanism by which BTX exerts clinical benefit. |
topic |
botulinum toxin basal ganglia dystonia ansa lenticularis white matter plasticity diffusion tensor imaging |
url |
https://www.frontiersin.org/article/10.3389/fneur.2019.00265/full |
work_keys_str_mv |
AT annejblood whitematterchangesincervicaldystoniarelatetoclinicaleffectivenessofbotulinumtoxintreatment AT annejblood whitematterchangesincervicaldystoniarelatetoclinicaleffectivenessofbotulinumtoxintreatment AT annejblood whitematterchangesincervicaldystoniarelatetoclinicaleffectivenessofbotulinumtoxintreatment AT annejblood whitematterchangesincervicaldystoniarelatetoclinicaleffectivenessofbotulinumtoxintreatment AT annejblood whitematterchangesincervicaldystoniarelatetoclinicaleffectivenessofbotulinumtoxintreatment AT annejblood whitematterchangesincervicaldystoniarelatetoclinicaleffectivenessofbotulinumtoxintreatment AT johnkkuster whitematterchangesincervicaldystoniarelatetoclinicaleffectivenessofbotulinumtoxintreatment AT johnkkuster whitematterchangesincervicaldystoniarelatetoclinicaleffectivenessofbotulinumtoxintreatment AT johnkkuster whitematterchangesincervicaldystoniarelatetoclinicaleffectivenessofbotulinumtoxintreatment AT johnkkuster whitematterchangesincervicaldystoniarelatetoclinicaleffectivenessofbotulinumtoxintreatment AT johnkkuster whitematterchangesincervicaldystoniarelatetoclinicaleffectivenessofbotulinumtoxintreatment AT jefflwaugh whitematterchangesincervicaldystoniarelatetoclinicaleffectivenessofbotulinumtoxintreatment AT jefflwaugh whitematterchangesincervicaldystoniarelatetoclinicaleffectivenessofbotulinumtoxintreatment AT jefflwaugh whitematterchangesincervicaldystoniarelatetoclinicaleffectivenessofbotulinumtoxintreatment AT jefflwaugh whitematterchangesincervicaldystoniarelatetoclinicaleffectivenessofbotulinumtoxintreatment AT jefflwaugh whitematterchangesincervicaldystoniarelatetoclinicaleffectivenessofbotulinumtoxintreatment AT jacobmlevenstein whitematterchangesincervicaldystoniarelatetoclinicaleffectivenessofbotulinumtoxintreatment AT jacobmlevenstein whitematterchangesincervicaldystoniarelatetoclinicaleffectivenessofbotulinumtoxintreatment AT jacobmlevenstein whitematterchangesincervicaldystoniarelatetoclinicaleffectivenessofbotulinumtoxintreatment AT trishajmulthauptbuell whitematterchangesincervicaldystoniarelatetoclinicaleffectivenessofbotulinumtoxintreatment AT lewisrsudarsky whitematterchangesincervicaldystoniarelatetoclinicaleffectivenessofbotulinumtoxintreatment AT lewisrsudarsky whitematterchangesincervicaldystoniarelatetoclinicaleffectivenessofbotulinumtoxintreatment AT hanscbreiter whitematterchangesincervicaldystoniarelatetoclinicaleffectivenessofbotulinumtoxintreatment AT hanscbreiter whitematterchangesincervicaldystoniarelatetoclinicaleffectivenessofbotulinumtoxintreatment AT hanscbreiter whitematterchangesincervicaldystoniarelatetoclinicaleffectivenessofbotulinumtoxintreatment AT hanscbreiter whitematterchangesincervicaldystoniarelatetoclinicaleffectivenessofbotulinumtoxintreatment AT hanscbreiter whitematterchangesincervicaldystoniarelatetoclinicaleffectivenessofbotulinumtoxintreatment AT hanscbreiter whitematterchangesincervicaldystoniarelatetoclinicaleffectivenessofbotulinumtoxintreatment AT hanscbreiter whitematterchangesincervicaldystoniarelatetoclinicaleffectivenessofbotulinumtoxintreatment AT nutansharma whitematterchangesincervicaldystoniarelatetoclinicaleffectivenessofbotulinumtoxintreatment AT nutansharma whitematterchangesincervicaldystoniarelatetoclinicaleffectivenessofbotulinumtoxintreatment AT nutansharma whitematterchangesincervicaldystoniarelatetoclinicaleffectivenessofbotulinumtoxintreatment |
_version_ |
1725323874474655744 |
spelling |
doaj-e01c2f4025cc42c6b60f44cfb70e98662020-11-25T00:31:05ZengFrontiers Media S.A.Frontiers in Neurology1664-22952019-04-011010.3389/fneur.2019.00265432363White Matter Changes in Cervical Dystonia Relate to Clinical Effectiveness of Botulinum Toxin TreatmentAnne J. Blood0Anne J. Blood1Anne J. Blood2Anne J. Blood3Anne J. Blood4Anne J. Blood5John K. Kuster6John K. Kuster7John K. Kuster8John K. Kuster9John K. Kuster10Jeff L. Waugh11Jeff L. Waugh12Jeff L. Waugh13Jeff L. Waugh14Jeff L. Waugh15Jacob M. Levenstein16Jacob M. Levenstein17Jacob M. Levenstein18Trisha J. Multhaupt-Buell19Lewis R. Sudarsky20Lewis R. Sudarsky21Hans C. Breiter22Hans C. Breiter23Hans C. Breiter24Hans C. Breiter25Hans C. Breiter26Hans C. Breiter27Hans C. Breiter28Nutan Sharma29Nutan Sharma30Nutan Sharma31Mood and Motor Control Laboratory, Massachusetts General Hospital (MGH), Charlestown, MA, United StatesLaboratory of Neuroimaging and Genetics, Massachusetts General Hospital, Charlestown, MA, United StatesDepartment of Neurology, Massachusetts General Hospital, Boston, MA, United StatesDepartment of Psychiatry, Massachusetts General Hospital, Boston, MA, United StatesMartinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown, MA, United StatesDepartment of Psychiatry, Harvard Medical School, Boston, MA, United StatesMood and Motor Control Laboratory, Massachusetts General Hospital (MGH), Charlestown, MA, United StatesLaboratory of Neuroimaging and Genetics, Massachusetts General Hospital, Charlestown, MA, United StatesDepartment of Neurology, Massachusetts General Hospital, Boston, MA, United StatesDepartment of Psychiatry, Massachusetts General Hospital, Boston, MA, United StatesMartinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown, MA, United StatesMood and Motor Control Laboratory, Massachusetts General Hospital (MGH), Charlestown, MA, United StatesDepartment of Neurology, Massachusetts General Hospital, Boston, MA, United StatesMartinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown, MA, United StatesDivision of Child Neurology, Boston Children's Hospital, Boston, MA, United StatesDepartment of Neurology, Harvard Medical School, Boston, MA, United StatesMood and Motor Control Laboratory, Massachusetts General Hospital (MGH), Charlestown, MA, United StatesDepartment of Psychiatry, Massachusetts General Hospital, Boston, MA, United StatesMartinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown, MA, United StatesDepartment of Neurology, Massachusetts General Hospital, Boston, MA, United StatesDepartment of Neurology, Harvard Medical School, Boston, MA, United StatesDepartment Neurology, Brigham and Women's Hospital, Boston, MA, United StatesMood and Motor Control Laboratory, Massachusetts General Hospital (MGH), Charlestown, MA, United StatesLaboratory of Neuroimaging and Genetics, Massachusetts General Hospital, Charlestown, MA, United StatesDepartment of Psychiatry, Massachusetts General Hospital, Boston, MA, United StatesMartinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown, MA, United StatesDepartment of Psychiatry, Harvard Medical School, Boston, MA, United States0Department of Radiology, Massachusetts General Hospital, Boston, MA, United States1Warren Wright Adolescent Center, Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, United StatesDepartment of Neurology, Massachusetts General Hospital, Boston, MA, United StatesDepartment of Neurology, Harvard Medical School, Boston, MA, United StatesDepartment Neurology, Brigham and Women's Hospital, Boston, MA, United StatesIn a previous report showing white matter microstructural hemispheric asymmetries medial to the pallidum in focal dystonias, we showed preliminary evidence that this abnormality was reduced 4 weeks after botulinum toxin (BTX) injections. In the current study we report the completed treatment study in a full-size cohort of CD patients (n = 14). In addition to showing a shift toward normalization of the hemispheric asymmetry, we evaluated clinical relevance of these findings by relating white matter changes to degree of symptom improvement. We also evaluated whether the magnitude of the white matter asymmetry before treatment was related to severity, laterality, duration of dystonia, and/or number of previous BTX injections. Our results confirm the findings of our preliminary report: we observed significant fractional anisotropy (FA) changes medial to the pallidum 4 weeks after BTX in CD participants that were not observed in controls scanned at the same interval. There was a significant relationship between magnitude of hemispheric asymmetry and dystonia symptom improvement, as measured by percent reduction in dystonia scale scores. There was also a trend toward a relationship between magnitude of pre-injection white matter asymmetry and symptom severity, but not symptom laterality, disorder duration, or number of previous BTX injections. Post-hoc analyses suggested the FA changes at least partially reflected changes in pathophysiology, but a dissociation between patient perception of benefit from injections and FA changes suggested the changes did not reflect changes to the primary “driver” of the dystonia. In contrast, there were no changes or group differences in DTI diffusivity measures, suggesting the hemispheric asymmetry in CD does not reflect irreversible white matter tissue loss. These findings support the hypothesis that central nervous system white matter changes are involved in the mechanism by which BTX exerts clinical benefit.https://www.frontiersin.org/article/10.3389/fneur.2019.00265/fullbotulinum toxinbasal gangliadystoniaansa lenticulariswhite matter plasticitydiffusion tensor imaging |